Author Archives: Modulight Content

About Modulight Content

Modulight wants to share high-quality scientific publications, white papers, application notes, and other articles. The articles shared are courtesy of the authoring researchers and groups and we're thankful for giving us the permission to honor their work this way. If you have something to share please drop us a line (see the contact form at Contact Us section).

Antimicrobial PDT for prosthetic joint infections

Motivation for the study Periprosthetic joint infections after hip and knee replacement surgeries are associated with high patient morbidity and a large financial cost. Challenging two-stage revision surgeries are required with long antibiotics regimes that can have limited efficacy and cannot eradicate drug-resistant strains like MRSA (methicillin-resistant Staphylococcus aureus). This study aims to investigate the potential of photodynamic therapy with methylene blue to eradicate problematic bacteria associated with joint infections.   Results Photos from the original publication. Reproduced under Creative Commons Attribution 4.0 International License. Continue reading →Customer case Royal National Orthopaedic Hospital at UCL, Stanmore in London, UK is an internationally leading Centre of Excellence and tertiary referral centre for complex orthopedic conditions. Close collaboration between clinicians and engineers facilitates high-quality research into orthopedic implant fixation and bone regeneration. The focus is on translational themes that include biomaterials, stem cells, the design and follow-up of implants, bone graft substitute materials and implant infections. PDT has been studied as an alternative to antibiotics to more effectively tackle infections following hip & knee Continue reading →

Protected: New approach for targeted PDT of glioblastoma

There is no excerpt because this is a protected post.Customer case Research in close collaboration with University Medical Center Utrecht, Erasmus Medical Center and Leiden University Medical Center. Research focused on the efficacy and mechanisms of targeted cancer photoimmunotherapy using nanobodies (antibody fragments). The advantage of nanobodies lies in the combination of their small molecular size, with high binding affinity for their targets, resulting to high accumulation at the tumor site, better tumor penetration and faster clearance from blood circulation. The aim is to target therapy to cancer cell-expressing antigens like EGFR (H&N cancer) Continue reading →

Photothermal therapy with platinum nanoparticles

Photothermal therapy efficiency Human ovarian cancer cells were plated on Petri dishes and incubated with platinum nanoparticles of varying sizes between 30 and 70 nm. After 24-hour incubation, irradiation was performed using a Modulight ML6600 laser at 808 nm together with an illumination kit (MLAKIT) tailored for Petri dish illumination. A small area of the dish was illuminated with the laser for five minutes with 45 W/cm2 irradiance. Calcein cell viability staining was performed 24 hours after the laser treatment and cells were examined with a Continue reading →Customer case Experimental Biophysics and Optical Manipulation research group studies biophysical properties of the cells using advanced optical techniques like optical trapping and nanoscale thermoplasmonics. Biophysical studies include the dynamics of plasma membrane, the effect of proteins on the membrane mechanisms of plasma membrane ruptures. Another important research area is photothermal therapy (PTT) using near-infrared laser to heat metallic nanoparticles. This heating of nanoparticles is also studied to deliver RNA therapeutics into the tumor tissue.  PET imaging is used to monitor treatment effects. Modulight products: ML6600 Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – July 2021

 Modulight Spotlights: LASER-SHARP RESEARCH – July 2021 Congratulations for Gina Manda and her team at Victor Babes National Institute of Pathology! Their genetic study unveiled a network of stress responses in tumor cells triggered by PDT. These results expand knowledge of different mechanisms behind therapy-induced cell death and treatment resistance. Read original publication   Modulight is very happy to be supporting this research. We would like to deliver our warmest congratulations to the research team!   #LaserSharpResearch  #ModulightInScience   #LasersInScience #KillCancer  #ColonCancer #Genetics     Continue reading →

Vision-sparing targeted phototherapy for uveal melanoma

Preliminary investigation of AU-011     Related Modulight products and Services   Related Publications Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens Rhonda C. Kines, Cynthia D. Thompson, Sean Spring, Zhenyu Li, Elisabet de los Pinos, Stephen Monks and John T. Schiller Cancer Immunology Research, 2021, 9 (6)   A Phase 1b/2 Open-label Clinical Trial to Evaluate the Safety and Efficacy of AU-011 for the Treatment of Choroidal Melanoma Prithvi Mruthyunjaya, Amy C. Schefler, Ivana K. Continue reading →Customer case Aura Biosciences, headquartered in Cambridge, MA, is developing a new class of photoactivated therapy for cancer patients together with National Cancer Institute, Emory Eye Center and Wills Eye Hospital. The therapy is based on virus-like conjugates and its primary indication is uveal melanoma. The goal is to eventually develop this technology for multiple cancer indications, such as non-muscle invasive bladder cancer (NMIBC), for which plans are underway to conduct a clinical trial. Dr. Carol Shields, MD – Aura Biosciences Dr. Rhonda Kines, PhD – Continue reading →

Combining photoimmunotherapy with immune checkpoint inhibition

Motivation for the study The motivation was to study if photoimmunotherapy could enhance anti-tumor immunity when combined with immune checkpoint inhibition. CD44-targeted photoimmunotherapy was applied against poorly immunogenic, “cold” tumor and antitumor effect was studied alone and in combination with anti-PD-1 immune checkpoint inhibition. Sensitization of this “cold” tumor to immune checkpoint inhibition after photoimmunotherapy would mean that the tumor has been converted into highly immunogenic, “hot” tumor infiltrated with killer T cells mainly responsible for eradicating the tumor. The formation of immunological antitumor memory Continue reading →Customer case The Laboratory of Molecular Theranostics at National Cancer Institute (NCI) is a major research section of the Molecular Imaging Program at National Cancer Institute (NCI) and is led by Dr. Hisataka Kobayashi who is the father of photoimmunotherapy. The ground-breaking research includes the development of imaging and theranostic probes with a particular emphasis on optical probes, which can aid in cancer detection during cancer resection or endoscopy. Dr. Hisataka Kobayashi M.D., PhD Dr. Peter L. Choyke M.D., PhD   Modulight products: ML7710 (multiple channels Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – June 2021

Modulight Spotlights: LASER-SHARP RESEARCH – June 2021 The findings by Prof. Lothar Lilge and his team might enable improved treatment of diffuse lung metastasis which are difficult to treat with standard therapies. A novel lung perfusion platform significantly reduced tissue absorption and allowed better light penetration, resulting in up to 3-fold increased treatment volumes.   Read original publication   Modulight is very happy to be supporting this research. We would like to deliver our warmest congratulations to the research team!   #LaserSharpResearch  #ModulightInScience   #LasersInScience Continue reading →

Light-emitting fabrics for dermatological diseases

    Related Modulight products and Services   Related Publications Light emitting fabrics for PDT: technology and results of clinical studies Serge R. Mordon, Elise Thecua, Fabienne Lecomte, Anne-Sophie Vignion-Dewalle, Pascal Deleporte, Cyril Maire, Henry Abi-Rached, Claire Vicentini, Theresa Hommel, R. Markus Szeimies, Laurent Mortier SPIE, 2019   Photodynamic Therapy Using a New Painless Light-Emitting Fabrics Device in the Treatment of Extramammary Paget Disease of the Vulva (the PAGETEX Study): Protocol for an Interventional Efficacy and Safety Trial Fabienne Lecomte, Elise Thecua, Laurine Ziane, Pascal Continue reading →Customer case Research by: Laser-assisted therapies and immunotherapies for oncology (OncoThAI) center at University of Lille is a large research center that carries fundamental and translational projects with the aim to widely implement PDT to clinical use either alone or in combination with other therapies like surgery or immunotherapy. Modulight products: ML7710 (631, 635, 665 nm) Laser use: Light-emitting fabrics for PDT therapy at clinical level   Prof. Serge Mordon PhD, currently at BioTis/Inserm     Dr. Laurent Mortier, MD, PhD, University of Lille   Research Continue reading →

Selective laser vaporization of polypropylene mesh in tissue

  Motivation for the study Surgical mesh is used to treat female stress urinary incontinence (SUI) and transvaginal pelvic organ prolapse (POP). However, erosion of this synthetic, non-absorbable mesh is a common complication and in more than half of these cases, a surgical excision of the mesh in the operating room is required. The mesh removal is technically challenging, may damage healthy adjacent tissues, and in some cases must be repeated several times. This study aims to explore the feasibility of selective laser vaporization, which Continue reading →Customer case University of North Carolina at Charlotte is a public research university founded in 1946. Department of Physics and Optical Science is dedicated on developing minimally invasive optics solutions for biomedical indications, such as tissue ablation, nerve simulation and surgical applications. Collaborations with Carolinas Medical Center at Charlotte and John Hopkins University at Maryland. Most recent research activities have focused on development of thulium fiber laser (TFL) as an alternative to the gold standard Holmium: YAG laser for lithotripsy (destruction of kidney stones), and Continue reading →

ML7710 for photoimmunotherapy against regulatory T cells in tumors

    Results Tumor growth was significantly suppressed by photoimmunotherapy, compared to control or IgG without light activation. Tumor growth suppression, as well as overall survival after photoimmunotherapy, were significantly better with F(ab´)2 fragments than with full IgG. This efficacy improvement might be related to killer T cells, which were detected in much higher numbers after photoimmunotherapy with F(ab´)2 fragments and are key cells for the generation of efficient systemic antitumor immunity.       Related Modulight products and Services   Related Publications The Effect Continue reading →Customer case The Laboratory of Molecular Theranostics is a major research section of the Molecular Imaging Program at National Cancer Institute (NCI) and is led by Dr. Hisataka Kobayashi. The groundbreaking research includes the development of imaging and theranostic probes, which can aid in cancer detection and treatment. Dr. Kobayashi has invented near-infrared photoimmunotherapy (NIR-PIT) with IRDye700DX, which is currently in FDA-designated fast-track Phase 3 trials for inoperable Head & Neck cancer. Dr. Hisataka Kobayashi M.D., PhD   Dr. Peter L. Choyke M.D., PhD   Continue reading →